Therapeutics

Tools

Back to the Top
Search By Attributes

Search Results

Name Synonyms FDA Status Company Target Type Therapy Type Approved
For
Aducanumab BIIB037 Alzheimer's Disease (Phase 3) Biogen, Neurimmune Amyloid-Related Immunotherapy (passive)
Crenezumab MABT5102A ,
RG7412
Alzheimer's Disease (Phase 3) AC Immune SA, Genentech, Hoffmann-La Roche Amyloid-Related Immunotherapy (passive) None
Gantenerumab RO4909832,
RG1450
Alzheimer's Disease (Phase 3) Chugai Pharmaceutical Co., Ltd., Hoffmann-La Roche Amyloid-Related Immunotherapy (passive)
Solanezumab LY2062430 Alzheimer's Disease (Phase 3) Eli Lilly & Co. Amyloid-Related Immunotherapy (passive) None